Developing 21st Century Medicines
Professor Moein Moghimi, PhD
Co-Founder, Executive Board Member and Chair, Science Advisory Board
EDITORIAL APPOINTMENTS
Editor-in-Chief, Drug Delivery (Taylor & Francis)
Editor-in-Chief, Journal of Nanotheranostics (Basel)
Associate Editor, Molecular Therapy (Cell Press)
Current other editorial board positions: Advanced Drug Delivery Reviews (Elsevier), Journal of Controlled Release (Elsevier) and Nanomedicine (Taylor & Francis).
DISTINCTIONS AND HONORS
Ranked among the world’s leading 50 scientists in Pharmacology & Pharmacy by the Stanford/Elsevier's career-long science-wide citation analysis and database.
Ranked 9th in the United Kingdom and 46th worldwide in Pharmacology & Pharmacy
Professor Moein Moghimi is an internationally recognized scientist in nanomedicine, drug delivery, pharmaceutical nanoscience and nanosafety. He is Professor of Pharmaceutics and Nanomedicine at Newcastle University and an Adjoint Professor at the University of Colorado Denver.
As Co-Founder of SMDG and inventor of the company’s proprietary NanoLigand™ platforms, Professor Moghimi provides scientific leadership across SMDG’s therapeutic programs. His work has informed the development of peptide-based, non-viral therapeutic systems designed to overcome biological barriers and enable more precise delivery of advanced medicines.
Throughout his career, Professor Moghimi has made foundational contributions to understanding how nanoparticles interact with the blood, immune system and tissues. His research encompasses complement biology, protein–nanoparticle interactions, immune and cellular safety, and the design of lymphotropic, splenotropic, phagocyte-resistant and brain-targeted nanosystems. This work has helped establish important principles for the Safe-by-Design development of nanomedicines.
Before joining Newcastle University, Professor Moghimi held senior academic and research positions at Durham University, the University of Copenhagen, Houston Methodist Research Institute, the University of Brighton and the University of Nottingham. At the University of Copenhagen, he founded and directed Denmark’s first interdisciplinary centre dedicated to pharmaceutical nanotechnology and nanotoxicology.
Professor Moghimi has authored more than 300 peer-reviewed scientific publications, contributed to multiple patents and delivered more than 300 invited lectures and keynote presentations in more than 30 countries. He has also advised pharmaceutical, biotechnology, healthcare and investment organisations, as well as governmental bodies and research councils internationally. He serves as Editor-in-Chief of the Journal of Drug Targeting.
Professor Moghimi earned his PhD in Biochemistry from Imperial College London and completed a Science and Engineering Research Council-funded postdoctoral fellowship in advanced drug delivery at the University of Nottingham.
Visit Professor Moein Moghimi's website